<DOC>
	<DOCNO>NCT00848250</DOCNO>
	<brief_summary>The purpose study determine whether ACE inhibitor alter fibrinolytic , inflammatory , hemodynamic response cardiopulmonary bypass infant child congenital heart disease .</brief_summary>
	<brief_title>Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass Infants Children</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Infants child ( newborn 17 year age ) undergo cardiopulmonary bypass elective surgical correction congenital heart defect . Patients must take ACE inhibitor prior operation Patients discontinue ACEIs deem unsafe primary cardiologist Any condition rendering subject legal guardian unable understand nature , scope , possible consequence study . Pregnancy rule standard care screen procedure . Individuals whose weight le 3.5 kg time enrollment . Inability comply protocol . ie . Children deem unsafe extra blood draw , child think noncompliant medication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cardiopulmonary Bypass</keyword>
	<keyword>ACE inhibitor</keyword>
	<keyword>Pediatrics</keyword>
</DOC>